| SAD and MAD Study of FTX-101 in Healthy Male Subjects (NCT06617546) | Find Therapeutics | 2024-10-14 |
| Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function (NCT06657560) | Shanghai Shengdi Pharmaceutical Co., Ltd | 2024-10-14 |
| Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (NCT06622590) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2024-10-13 |
| An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors (NCT06568614) | BeOne Medicines | 2024-10-12 |
| To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects (NCT06598956) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-10-12 |
| Thyme Honey for Management of Oral Lichen Planus (NCT06810752) | British University In Egypt | 2024-10-12 |
| First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers (NCT06625515) | Accent Therapeutics | 2024-10-11 |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia (NCT05849662) | Therapeutic Advances in Childhood Leukemia Consortium | 2024-10-11 |
| Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents (NCT06575738) | University of Colorado, Denver | 2024-10-11 |
| The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) (NCT06656962) | Renmin Hospital of Wuhan University | 2024-10-10 |
| A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma (NCT07599371) | The First Affiliated Hospital of Zhengzhou University | 2024-10-10 |
| Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. (NCT06600022) | Sinocelltech Ltd. | 2024-10-10 |
| Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC (NCT06434103) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-10-10 |
| A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects (NCT06619873) | Shandong Suncadia Medicine Co., Ltd. | 2024-10-10 |
| PK/PD of Digoxin in Infants With SVHD (NCT06613477) | Duke University | 2024-10-10 |
| Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies. (NCT06812104) | Kyowa Kirin Co., Ltd. | 2024-10-10 |
| A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants (NCT06619483) | Bayer | 2024-10-10 |
| Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis (NCT06619990) | Xencor, Inc. | 2024-10-10 |
| A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors (NCT06544655) | Bristol-Myers Squibb | 2024-10-10 |
| A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus (NCT06535412) | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | 2024-10-10 |
| Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) (NCT06434350) | M.D. Anderson Cancer Center | 2024-10-10 |
| A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients (NCT06557174) | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | 2024-10-10 |
| Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks (NCT07099222) | University of Arizona | 2024-10-10 |
| InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia (NCT05961059) | Leiden University Medical Center | 2024-10-10 |
| A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus (NCT06362265) | Eli Lilly and Company | 2024-10-10 |
| Tissue Therapy of Transsphincteric Anal Fistula (NCT06303752) | University of Southern Denmark | 2024-10-09 |
| Regenn® Therapy System Safety Study (NCT06259409) | Progenerative Medical, Inc | 2024-10-09 |
| 5G-EMERALD: Amivantamab in Malignant Brain Tumours (NCT06632236) | Institute of Cancer Research, United Kingdom | 2024-10-09 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects (NCT07057726) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2024-10-09 |
| Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS (NCT05823480) | City of Hope Medical Center | 2024-10-09 |
| Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression (NCT06506019) | University Health Network, Toronto | 2024-10-09 |
| Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer (NCT06321484) | Dana-Farber Cancer Institute | 2024-10-09 |
| JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) (NCT06675422) | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2024-10-09 |
| A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia (NCT06525636) | Kyowa Kirin Co., Ltd. | 2024-10-09 |
| Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC (NCT06088771) | Icahn School of Medicine at Mount Sinai | 2024-10-09 |
| Study of LM-299 in Subjects Advanced Malignant Tumors (NCT06650566) | LaNova Medicines Limited | 2024-10-09 |
| Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (NCT06511050) | Icahn School of Medicine at Mount Sinai | 2024-10-09 |
| Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa (NCT06361836) | Sonoma Biotherapeutics, Inc. | 2024-10-09 |
| Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years (NCT06583031) | Sanofi Pasteur, a Sanofi Company | 2024-10-09 |
| PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (NCT05805371) | City of Hope Medical Center | 2024-10-09 |
| Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors (NCT06617169) | Monopar Therapeutics | 2024-10-08 |
| Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant (NCT06928779) | Corcept Therapeutics | 2024-10-08 |
| M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (NCT06509906) | EMD Serono Research & Development Institute, Inc. | 2024-10-08 |
| Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects (NCT06625710) | GemVax & Kael | 2024-10-08 |
| A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas (NCT06660056) | GONGCHU Biotechnology Co., Ltd | 2024-10-08 |
| Mass Balance Clinical Trial With TEV-56286 (NCT06627231) | Teva Branded Pharmaceutical Products R&D, Inc. | 2024-10-08 |
| SXC-2023 Cocaine Interaction Study (NCT06343532) | National Institute on Drug Abuse (NIDA) | 2024-10-08 |
| Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors (NCT06667141) | Acrivon Therapeutics | 2024-10-08 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma (NCT06102525) | Rznomics, Inc. | 2024-10-08 |
| The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation (NCT06561880) | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-08 |
| Study Investigating the Safety, Tolerability and Blood Concentration of the Substance SR-878 (NCT06607484) | SciRhom GmbH | 2024-10-08 |
| A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers (NCT06632938) | AbbVie | 2024-10-08 |
| An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). (NCT06335979) | Novartis Pharmaceuticals | 2024-10-08 |
| Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas (NCT06623201) | Nathalie Zeitouni | 2024-10-07 |
| Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (NCT06598306) | Amgen | 2024-10-07 |
| A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum (NCT06267872) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-07 |
| A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib (NCT06625489) | GlaxoSmithKline | 2024-10-07 |
| Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults (NCT06585891) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-07 |
| A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. (NCT07155499) | AO GENERIUM | 2024-10-07 |
| A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031) (NCT06597760) | Merck Sharp & Dohme LLC | 2024-10-07 |
| Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants (NCT06566768) | Bristol-Myers Squibb | 2024-10-07 |
| A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants (NCT06681441) | QurAlis Corporation | 2024-10-07 |
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors (NCT06631079) | NEC Bio B.V | 2024-10-07 |
| Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers (NCT04954989) | Megalabs | 2024-10-06 |
| Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers (NCT06613139) | Yuhan Corporation | 2024-10-06 |
| Tislelizumab with Azacitidine in the Treatment of R/R AML (NCT06586099) | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-05 |
| miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial (NCT06285253) | Miromatrix Medical Inc. | 2024-10-05 |
| A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors (NCT06605222) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-10-04 |
| CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) (NCT06420089) | Vittoria Biotherapeutics | 2024-10-04 |
| Clinical Trial to Evaluate the PK Interactions of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy Volunteers (NCT06623526) | Yuhan Corporation | 2024-10-04 |
| Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet (NCT06369571) | Johns Hopkins University | 2024-10-04 |
| Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia (NCT06392711) | University of Wisconsin, Madison | 2024-10-04 |
| A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants (NCT06625671) | DualityBio Inc. | 2024-10-04 |
| Recombinant vWF Concentrate and ECMO (NCT06118372) | University of Virginia | 2024-10-03 |
| A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin (NCT06625307) | Novo Nordisk A/S | 2024-10-03 |
| ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer (NCT06825624) | Hansoh BioMedical R&D Company | 2024-10-03 |
| A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003) (NCT06586606) | Merck Sharp & Dohme LLC | 2024-10-03 |
| A Study of BG-C477 in Participants With Advanced Solid Tumors (NCT06596473) | BeOne Medicines | 2024-10-03 |
| Phase I Study to Evaluate rhTPO in Healthy Caucasian Volunteers (NCT06630494) | 3SBIO AU PTY LTD | 2024-10-03 |
| Bioavailability Study of XS003 (Nilotinib) (NCT07138352) | Xspray Pharma AB | 2024-10-03 |
| Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma (NCT07139509) | Xi'an No.3 Hospital | 2024-10-03 |
| ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT06351644) | Adriana Rossi | 2024-10-02 |
| A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 (NCT06616766) | Yuhan Corporation | 2024-10-02 |
| Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS (NCT07095686) | n-Lorem Foundation | 2024-10-02 |
| Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy (NCT06224660) | Sardocor Corp. | 2024-10-02 |
| Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors (NCT03988283) | Washington University School of Medicine | 2024-10-02 |
| Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) (NCT06684379) | PEACHES BIOTECH | 2024-10-02 |
| The Anesthetic and Analgesic Effect of Adjunct Liposomal Bupivacaine in Periodontal Surgical Procedures (NCT07725731) | The University of Texas Health Science Center at San Antonio | 2024-10-02 |
| A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV (NCT06652958) | ViiV Healthcare | 2024-10-02 |
| Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020) (NCT06596668) | Merck Sharp & Dohme LLC | 2024-10-02 |
| Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias (NCT05286255) | Medical University of South Carolina | 2024-10-01 |
| An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration (NCT06645704) | Escient Pharmaceuticals, Inc | 2024-10-01 |
| A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver (NCT05202353) | Boehringer Ingelheim | 2024-10-01 |
| Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC (NCT06222593) | State University of New York at Buffalo | 2024-10-01 |
| Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315 (NCT06592495) | Daewoong Pharmaceutical Co. LTD. | 2024-10-01 |
| The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain (NCT06614608) | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 2024-10-01 |
| Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma (NCT06485908) | Assistance Publique Hopitaux De Marseille | 2024-10-01 |
| A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects (NCT06547359) | NewAmsterdam Pharma | 2024-10-01 |
| VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS (NCT06471946) | Navy General Hospital, Beijing | 2024-10-01 |
| A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity (NCT06564441) | Boehringer Ingelheim | 2024-10-01 |